Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxalta GmbH
Takeda Pharmaceutical Co Ltd
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008286361Aexternal-prioritypatent/AU2008286361B2/en
Application filed by Baxalta GmbH, Takeda Pharmaceutical Co Ltd, Baxalta IncfiledCriticalBaxalta GmbH
Priority to AU2013276993ApriorityCriticalpatent/AU2013276993B9/en
Publication of AU2013276993A1publicationCriticalpatent/AU2013276993A1/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATEDreassignmentBaxalta GmbHRequest for AssignmentAssignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Application grantedgrantedCritical
Publication of AU2013276993B2publicationCriticalpatent/AU2013276993B2/en
Publication of AU2013276993B9publicationCriticalpatent/AU2013276993B9/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITEDreassignmentTAKEDA PHARMACEUTICAL COMPANY LIMITEDRequest for AssignmentAssignors: Baxalta GmbH, BAXALTA INCORPORATED
AU2013276993A2007-08-132013-12-24IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
CeasedAU2013276993B9
(en)